Phesi

Phesi Adds Clinical Trials Country Selection to ClinSite

East Lyme, Connecticut, USA: Phesi, a data-driven provider of clinical development analytics products and solutions, today announced a new country selection functionality has been added to ClinSite, its platform to provide investigator site intelligence to clients, enabling investigator site selection and management. The new functionality has been added in response to the industry-wide problem of non-performing countries and sites being…

7 (Demo)

When will companies stop babysitting the NANNIs for their clinical trials? 5 key takeaways from SCOPE 2020

SCOPE continues to be a central location for industry colleagues to meet and exchange ideas around clinical development. We had a great time at the 2020 meeting catching up with friends, clients and colleagues, as well as co-moderating a roundtable on protocol design and chairing a main session on site selection with esteemed industry practitioners. It was a whirlwind of…

OncoSec Secures Phesi ClinSite™ License to Select Clinical Trial Investigator Sites

EAST LYME, Conn. Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered…

Dan Manak joins Phesi

EAST LYME, Conn. Phesi is delighted to announce the appointment of Dan Manak to the role of Executive Director for Business Development. Dan is based in the US and has been working in pharma and clinical research for over 20 years, selling advanced clinical data analytics and AI technology and services to sponsor companies, enabling site selection and site management. On…

ai-is-the-next-step-in-human-evolution.001

A Lot To Be Thankful For

As we head into Thanksgiving, we reflect upon all we have accomplished since January and our vision for 2020. At Phesi, we had quite a few firsts in 2019 and much to be thankful for, such as: Successfully launching our flagship product, ClinSite™ – a self-service, artificial intelligence (AI)-powered tool that enables biopharmaceutical companies to search for and select top-performing…

79d18b_23cffd755ae14586a71822aae7b8fb83~mv2

Patient Recruitment for Melanoma Immunotherapy Trial

Situation An innovative biotech company that specializes in developing DNA-based intratumoral immunotherapies needed help in recruiting patients unresponsive to anti-PD-1 therapy into a stage III/IV melanoma trial. Analysis Phesi worked with the CEO and Chief Clinical and Regulatory Officer over a 4-week period to conduct a competitive analysis, reviewing enrollment rates in top recruiting centers across 39 recent, relevant trials: Phesi…

imf

Integrated Clinical Development Planning for Iron Overload Candidate

Situation An exciting biotechnology company that develops gene therapeutic technology based on RNA wanted to develop a baseline, integrated development plan for a lead iron overload (IO) candidate.  The client was keen to take a data led approach to understand and document the following: Competitor activity, dosing and development status, including relevant input for strategic business development activities and interactions…

case-2

Cardiovascular Study Protocol Feasibility

Situation Phesi’s client was designing and planning a Phase II study for a unique cardiovascular (CV) indication. Its compound was first in class, and the first to target a particular CV dysfunction. The client requested insights from similar historical studies to consider what may impact trial operational performance. Analysis Phesi selected 37 trials from its comprehensive clinical trial database, with…

img

Troubleshooting an Under-Performing GI Trial

Situation A global pharmaceutical company was experiencing significant recruitment challenges in a priority Phase III gastroenterology trial, as competitors were running concurrent studies in the same patient population. Site activation was significantly below expectations for this type of trial, and the CRO was proposing to add further sites – despite resources spread thin and with budgets under pressure. The company brought…